详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, Sichuan, China. [4]Faculty of Dentistry, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.

出处：

DOI：

ISSN：

关键词： extracellular HSP70 cancer biomarker treatment vaccine

摘要：

Heat shock protein 70 (HSP70) is a highly conserved protein functioning as a "molecular chaperone", which is integral to protein folding and maturation. In addition to its high expression within cells upon stressful challenges, HSP70 can be translocated to the cell membrane or released from cells in free form or within extracellular vesicles (EVs). Such trafficking of HSP70 is also present in cancer cells, as HSP70 is overexpressed in various types of patient samples across a range of common malignancies, signifying that extracellular HSP70 (eHSP70) can serve as a tumor biomarker. eHSP70 is involved in a broad range of cancer-related events, including cell proliferation and apoptosis, extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition (EMT), angiogenesis, and immune response. eHSP70 can also induce cancer cell resistance to various treatments, such as chemotherapy, radiotherapy, and anti-programmed death-1 (PD-1) immunotherapy. Though the role of eHSP70 in tumors is contradictory, characterized by both pro-tumor and anti-tumor effects, eHSP70 serves as a promising target in cancer treatment. In this review, we comprehensively summarized the current knowledge about the role of eHSP70 in cancer progression and treatment resistance and discussed the feasibility of eHSP70 as a cancer biomarker and therapeutic target.Copyright © 2024 Hu, Liu, Zhao and Zhang.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [2]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]mRNA Vaccine-A New Cancer Treatment Strategy [2]转移性去势抵抗性前列腺癌临床治疗标志物——雄激素受体剪接变异体7 [3]CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer. [4]乳腺癌相关成纤维细胞：乳腺癌治疗的新靶点 [5]Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. [6]Bioinspired Tumor-Targeting and Biomarker-Activatable Cell-Material Interfacing System Enhances Osteosarcoma Treatment via Biomineralization [7]Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer [8]EPYC functions as a novel prognostic biomarker for pancreatic cancer [9]Personalized nanovaccines for treating solid cancer metastases [10]CRC-EBD: Epigenetic Biomarker Database for Colorectal Cancer